# NCT05132777 (NCT05132777)

> Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05132777
- Phase: PHASE2
- Status: UNKNOWN
- Sponsor: Shanghai JMT-Bio Inc.
- Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer; EGFR Exon20 Insertion Mutations
- Interventions: JMT101; Osimertinib Mesylate Tablets
- Enrollment: 155
- Primary outcome: Confirmed Objective Response Rate (ORR) Assessed by Blinded Independent Review Committee (IRC) per RECIST Version 1.1

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05132777